Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

Simple item page
dc.contributor.buuauthorAtasayar, Gülfer
dc.contributor.buuauthorEryılmaz, Işıl Ezgi
dc.contributor.buuauthorKarlı, Necdet
dc.contributor.buuauthorEgeli, Ünal
dc.contributor.buuauthorZarifoğlu, Mehmet
dc.contributor.buuauthorÇeçener, Gülşah
dc.contributor.buuauthorTaşkapılıoğlu, Özlem
dc.contributor.buuauthorTunca, Berrin
dc.contributor.buuauthorYıldırım, Öznur
dc.contributor.buuauthorAk, Seçil
dc.contributor.buuauthorTezcan, Gülçin
dc.contributor.buuauthorCan, Fatma Ezgi
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-1619-6680tr_TR
dc.contributor.orcid0000-0002-3820-424Xtr_TR
dc.contributor.orcid0000-0002-3316-316Xtr_TR
dc.contributor.orcid0000-0001-7904-883Xtr_TR
dc.contributor.orcid0000-0002-1953-7735tr_TR
dc.contributor.orcid0000-0002-5956-8755tr_TR
dc.contributor.researcheridABI-6078-2020tr_TR
dc.contributor.researcheridAAP-9988-2020tr_TR
dc.contributor.researcheridAAH-1656-2021tr_TR
dc.contributor.researcheridGWV-3548-2022tr_TR
dc.contributor.researcheridAAH-3843-2020tr_TR
dc.contributor.researcheridF-8554-2017tr_TR
dc.contributor.researcheridAAH-1420-2021tr_TR
dc.contributor.scopusid57189387392tr_TR
dc.contributor.scopusid57189380840tr_TR
dc.contributor.scopusid6506587942tr_TR
dc.contributor.scopusid55665145000tr_TR
dc.contributor.scopusid6603411305tr_TR
dc.contributor.scopusid6508156530tr_TR
dc.contributor.scopusid23037226400tr_TR
dc.contributor.scopusid6602965754tr_TR
dc.contributor.scopusid57189390647tr_TR
dc.contributor.scopusid55253485700tr_TR
dc.contributor.scopusid25650627600tr_TR
dc.contributor.scopusid56689608500tr_TR
dc.date.accessioned2022-12-12T12:02:03Z
dc.date.available2022-12-12T12:02:03Z
dc.date.issued2016-05-11
dc.description.abstractProphylactic therapy response varies in migraine patients. The present study investigated the relationship between the resistance to the drugs commonly used in prophylactic therapy and the possible polymorphic variants of proteins involved in the metabolism of these drugs. Migraine patients with the MDR1 3435TT genotype exhibited a better treatment response to topiramate than migraine patients with the CC and CT genotypes (p = 0.020). The MDR1 C3435T polymorphism was also found to be a higher risk factor for topiramate treatment failure in a comparison of the number of days with migraine (beta(2) = 1.152, p = 0.015). However, there was no significant relationship between the treatment response to topiramate and either the CYP2D6 or CYP2C19 polymorphism, and there were no significant correlations between the treatment responses to amitriptyline, propranolol, and valproic acid and the MDR1, CYP2D6 and CYP2C19 gene polymorphisms. This is the first study to investigate the effect of the polymorphic variants on prophylactic therapy response in migraine patients.en_US
dc.identifier.citationAtasayar, G. vd. (2016). "Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response". Journal of the Neurological Sciences, 366, 149-154.en_US
dc.identifier.endpage154tr_TR
dc.identifier.issn0022-510X
dc.identifier.issn1878-5883
dc.identifier.pubmed27288795tr_TR
dc.identifier.scopus2-s2.0-84969944998tr_TR
dc.identifier.startpage149tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.jns.2016.05.019
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0022510X16302787
dc.identifier.urihttp://hdl.handle.net/11452/29826
dc.identifier.volume366tr_TR
dc.identifier.wos000379105400030
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.journalJournal of the Neurological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectMigraineen_US
dc.subjectProphylactic therapy responseen_US
dc.subjectMDR1en_US
dc.subjectPolymorphismen_US
dc.subjectMultidrug-resistanceen_US
dc.subjectC3435t polymorphismen_US
dc.subjectCytochrome-P450en_US
dc.subjectFrequencyen_US
dc.subjectAllelesen_US
dc.subjectPharmacogeneticsen_US
dc.subjectPhenotypeen_US
dc.subjectGenotypeen_US
dc.subject2C19en_US
dc.subject2D6en_US
dc.subject.emtreeAmitriptylineen_US
dc.subject.emtreeCytochrome P450 2C19en_US
dc.subject.emtreeCytochrome P450 2D6en_US
dc.subject.emtreeGenomic DNAen_US
dc.subject.emtreeMultidrug resistance protein 1en_US
dc.subject.emtreePropranololen_US
dc.subject.emtreeTopiramateen_US
dc.subject.emtreeValproic aciden_US
dc.subject.emtreeABCB1 protein, humanen_US
dc.subject.emtreeCentral nervous system agentsen_US
dc.subject.emtreeCYP2C19 protein, humanen_US
dc.subject.emtreeCytochrome P450 2C19en_US
dc.subject.emtreeCytochrome P450 2D6en_US
dc.subject.emtreeFructoseen_US
dc.subject.emtreeMultidrug resistance proteinen_US
dc.subject.emtreeTopiramateen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeDNA polymorphismen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGene frequencyen_US
dc.subject.emtreeGenetic associationen_US
dc.subject.emtreeGenotypeen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMigraineen_US
dc.subject.emtreeMigraine with auraen_US
dc.subject.emtreeMigraine without auraen_US
dc.subject.emtreeMonotherapyen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProphylaxisen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeAnalogs and derivativesen_US
dc.subject.emtreeDrug resistanceen_US
dc.subject.emtreeGenetic association studyen_US
dc.subject.emtreeGenetic polymorphismen_US
dc.subject.emtreeGeneticsen_US
dc.subject.emtreeMigraine disordersen_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.meshAdulten_US
dc.subject.meshAmitriptylineen_US
dc.subject.meshCentral nervous system agentsen_US
dc.subject.meshCytochrome P-450 CYP2C19en_US
dc.subject.meshCytochrome P-450 CYP2D6en_US
dc.subject.meshDrug resistanceen_US
dc.subject.meshFemaleen_US
dc.subject.meshFructoseen_US
dc.subject.meshGene frequencyen_US
dc.subject.meshGenetic association studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMigraine disordersen_US
dc.subject.meshP-glycoproteinsen_US
dc.subject.meshPolymorphism, geneticen_US
dc.subject.meshPropranololen_US
dc.subject.meshRisk factorsen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshValproic aciden_US
dc.subject.scopusDrug Resistant Epilepsy; Epilepsy; Carbamazepineen_US
dc.subject.wosClinical neurologyen_US
dc.subject.wosNeurosciencesen_US
dc.titleAssociation of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment responseen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus